Literature DB >> 26153991

Migraine mAbs crowd into late-stage trials.

Gunjan Sinha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26153991     DOI： 10.1038/nbt0715-676c

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

Authors:  David W Dodick; Peter J Goadsby; Egilius L H Spierings; Joel C Scherer; Steven P Sweeney; David S Grayzel
Journal:  Lancet Neurol       Date:  2014-08-10       Impact factor: 44.182

2.  Anti-CGRP antibodies for migraine turn industry heads.

Authors:  Suzanne Elvidge
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

3.  Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Authors:  David W Dodick; Peter J Goadsby; Stephen D Silberstein; Richard B Lipton; Jes Olesen; Messoud Ashina; Kerri Wilks; David Kudrow; Robin Kroll; Bruce Kohrman; Robert Bargar; Joe Hirman; Jeff Smith
Journal:  Lancet Neurol       Date:  2014-10-05       Impact factor: 44.182
  3 in total
  3 in total

1.  Amgen's migraine antibody advances.

Authors: 
Journal:  Nat Biotechnol       Date:  2016-11-08       Impact factor: 54.908

2.  Efficacy of (S)-Lacosamide in preclinical models of cephalic pain.

Authors:  Aubin Moutal; Nathan Eyde; Edwin Telemi; Ki Duk Park; Jennifer Y Xie; David W Dodick; Frank Porreca; Rajesh Khanna
Journal:  Pain Rep       Date:  2016-06

3.  Migraine and subsequent chronic kidney disease risk: a nationwide population-based cohort study.

Authors:  Shuo-Chun Weng; Chia-Lin Wu; Chew-Teng Kor; Ping-Fang Chiu; Ming-Ju Wu; Chia-Chu Chang; Der-Cherng Tarng
Journal:  BMJ Open       Date:  2017-12-27       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.